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SIGNIFICANCE
Aggressive T-cell lymphomas with primary manifestation 
in the skin are rare and often harbour major diagnostic/
therapeutic challenges. In this retrospective descriptive 
monocentric cross-sectional case study over a period of 4 
years, we identified a total of 4 patients suffering from ag-
gressive T-cell lymphomas with primary manifestation in 
the skin. This corresponded to < 1% of all newly diagnosed 
cutaneous lymphoma cases. We observed an aggressive 
disease course in all our patients and disease progression 
and resistance to chemotherapy in two of them. Our report 
emphasizes the importance of an early extensive diagnostic 
work-up and a prompt aggressive therapeutic approach.
Rare T- or NK-cell lymphomas with cutaneous manifes-
tation may display a highly aggressive clinical course 
and major diagnostic/therapeutic challenges. This re-
port describes our experiences with different lympho-
mas of this rare category and the therapeutic options 
used. This retrospective, descriptive, monocentric, 
cross-sectional case study, identified 4 rare aggressive 
T-/NK-cell lymphomas with manifestation in the skin, 
which were diagnosed in a tertiary care centre over a 
period of 4 years. Two patients had an Epstein-Barr 
virus-associated extranodal NK/T-cell lymphoma and 
2 patients had a primary cutaneous CD8+ aggressive 
epidermotropic cytotoxic T-cell lymphoma. Concomi-
tant extracutaneous involvement was observed in 2 
of all 4 patients. Two patients had fulminant disease 
progression and resistance to chemotherapy. Two pa-
tients underwent allogeneic haematopoietic stem cell 
transplantation, which resulted in one complete remis-
sion and one partial remission. This report emphasizes 
the importance of an early diagnostic work-up and a 
prompt aggressive therapeutic approach. 
Key words: lymphoma; manifestation in the skin; ENKTL; PC-
AETCL; allogeneic hematopoietic stem cell transplantation.
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Mature T- and NK-cell malignancies are rare. However, in the skin, approximately 75% of all 
cutaneous lymphoma are of T-cell (approximately 65%) 
and NK-cell (approximately 10%) origin (1–5). Most of 
the T-cell lymphomas manifesting in the skin are primary 
cutaneous, i.e. originating from cells with skin-homing 
capacity that either permanently resides in the skin or 
recirculates through the blood (6, 7). Skin manifestation 
occurs in rare cases as the first clinical appearance of 
peripheral T-cell lymphomas (8, 9).
The 2008 WHO classification, revised in 2016, recog-
nizes extranodal NK/T-cell lymphoma (ENKTL) as one 
of the prototypes of virally associated Epstein-Barr virus 
(EBV)-positive T-cell or NK-cell lymphoma (9–12). 
ENKTL, nasal type affects adult individuals  and is more 
frequent in Asia, Mexico and South America, where it 
accounts for up to 6% of all cases of non-Hodgkin’s 
lymphomas (13). Males are affected 2–3 times more often 
than females (14). ENKTL nasal type manifests mostly 
in the nasal/paranasal area and can further involve the 
skin, gastrointestinal tract and, in rare cases, the bone 
marrow (15). An extranasal manifestation of ENKTL is 
less common, resulting in the suggestion of some authors 
that, in most cases of extranasal ENKTL, an occult nasal 
involvement was missed on initial evaluation/staging (9, 
16–18). The prototypic immunophenotype of ENKTL 
is CD2+CD56+. Surface CD3 and other common T-cell 
antigens (CD4, CD8, CD5) are usually negative with 
positivity for cytoplasmic CD3ε. Some tumours express 
α/β-T-cell receptor (α/β-TCR). γ/δ TCR expression has 
rarely been reported and molecular analysis only rarely 
detects a monoclonal rearrangement of the TCR gene 
(19). Overall patient survival and clinical features seem 
to be similar in T- and NK-cell phenotype ENKTL (20). 
Characteristically, EBV can be detected in almost all 
cases of ENKTL (21).
The prognosis of ENKTL depends on the disease stage. 
Disease manifestation outside the site of initial tumour 
manifestation is associated with poor prognosis (15). 
Elevated levels of lactate dehydrogenase and systemic 
symptoms of fever, malaise and weight loss are additio-
nal, independent poor prognostic factors (22).
Primary cutaneous CD8+ aggressive epidermotropic 
cytotoxic T-cell lymphoma (PC-AETCL) has been 
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recognized as a provisional entity in the 2016 revision 
of the WHO classification of lymphoid neoplasms (9, 
12). CD8+ cytotoxic T lymphocytes with pronounced 
epidermotropism and an aggressive clinical course are 
hallmarks of this lymphoma entity. The tumour affects 
adult individuals, but a case of primary cutaneous CD8+ 
PC-AETCL in a child has been reported (23). The pro-
totypic immunophenotype of this lymphoma entity is 
CD3+/CD4–/CD8+ with monoclonal rearrangement of 
the TCR gene. Tumour cells express cytotoxic molecu-
les (TIA-1+, granzyme B+) and the α/β-TCR. NK cell 
markers (CD56) and γ/δ TCR are not expressed, and 
EBV is not detectable, in neoplastic cells. In some cases, 
expression of pan-T-cell-markers may be lost (24). The 
estimated 5-year survival of patients with PC-AETCL 
is 0%. 
Other rare types of aggressive NK/T-cell lymphomas 
that can primarily manifest in the skin include angioim-
munoblastic T-cell lymphoma, primary cutaneous γ/δ 
T-cell lymphoma and severe hydroa vacciniforme-like 
T-cell lymphoma (a sub-entity in the group of hydroa 
vacciniforme-like lymphoproliferative disease) (25–27).
The diagnostic and therapeutic handling of these rare 
aggressive cutaneous T- and NK-cell lymphomas re-
presents a major hurdle in clinical practice. The aim of 
this report is to describe our experiences with different 
lymphoma cases of this category, emphasizing their very 
particular clinical features and/or therapeutic approaches. 
METHODS
For this retrospective, descriptive, monocentric, cross-sectional 
case study, a comprehensive search of the patients’ data repository 
of a tertiary care centre covering a population of approximately 
1.6 million people (University Hospital Zurich: approximately 1.5 
million; Kantonsspital St Gallen: approximately 0.1 million) was 
performed for the period between 1 January 2013 and 1 January 
2017. All identified patients with aggressive rare T-cell lympho-
mas with primary manifestation in the skin (definition according 
to the International Classification of Diseases, Tenth Revision 
code C84.4) were included in the study. We identified a total of 4 
individuals with aggressive rare T-cell lymphomas with primary 
manifestation in the skin.
RESULTS AND CLINICAL REPORTS
Between 1 January 2013 and 1 January 2017 a total of 
53 cutaneous T-cell lymphomas were diagnosed at our 
tertiary cutaneous lymphoma centre, which covers a 
population of approximately 1.6 million people (inci-
dence: 0.83 per 100,000 person-years). Four of these 
were aggressive rare T-cell lymphomas with primary 
manifestation in the skin, thus accounting for < 1% of 
all newly diagnosed cutaneous T-cell lymphomas. The 
following 4 aggressive rare T-cell lymphomas with pri-
mary manifestation in the skin were identified (Table 
I): (i) EBV-associated ENKTL nasal type with γ/δ TCR 
expression; (ii) EBV-associated extranasal ENKTL; 
(iii) PC-AETCL with an aberrant phenotype; and (iv) 
PC-AETCL. The mean age of the patients was 67.75 
years (ranging from 51 to 87 years). Three out of 4 
patients were female, 1 was male. The mean time from 
the first clinical symptoms to final diagnosis was 5.75 
months (range 2–12 months). All patients had an initial 
skin manifestation, with a concomitant extracutaneous 
involvement of the spine, bone marrow and/or lymph 
nodes in 2 out of 4 cases.
In 2 of the patients, fulminant disease progression and 
resistance to chemotherapy led to the patients’ death 64 
and 93 days after diagnosis, respectively. In 2 of the 
patients, allogeneic haematopoietic stem cell transplanta-
tion (HSCT) resulted in complete/partial remission for 9 
months and 18 months followed by a relapse. Apart from 
mild mixed acute and chronic graft-versus-host-disease 
Table I. Patient characteristics and disease courses
Case 1 Case 2 Case 3 Case 4
Demographics
  Age at diagnosis, years
    Mean: 67.75 years (51–87)
87 51 69 56
  Sex F F F M
Diagnostic details
  Diagnosis Nasal-type EBER+ENKTL Extranasal EBER+ ENKTL PC-AETCL, aberrant phenotype PC-AETCL
  Time to diagnosis (months) 2 2.5 3 4
  Systemic involvement Palatine tonsil, left mandible, spine No No Bone marrow, lymph nodes
Treatments
  Treatment 1 None Radiation therapy (6×20 Gy) Class IV corticosteroids disinfectants R-CHOEP
  Treatment 2 MTX s.c. (15 mg/week)
Interferon (3×3 million I.U.)
Radiotherapy
Bexarotene (300 mg/day)
MTX (20 mg/week)
Radiotherapy
Allogeneic HSCT (HLA-
identical)
  Treatment 3 MTX/Asp/Dexa Caelyx (20 mg/m2)
  Treatment 4 SMILE (with Pep-Arg)
  Treatment 5 Allogeneic HSCT
Current status Death from progress Death from progress Death from sepsis Death from progress and 
sepsis
Time after diagnosis, days 64 704 93 599
EBER: Epstien-barr virus-encoded small nuclear RNA; ENKTL: extranodal NK/T-cell lymphoma; PC-AETCL: primary cutaneous CD8+ aggressive epidermotropic cytotoxic 
T-cell lymphoma; HLA: human leukocyte antigen; SMILE: ; s.c.: subcutaneous; MTX/Asp/Dexa: ; I.U.: international units; MTX: methotrexate; HSCT: hematopoietic 
stem cell transplantation; R-CHOEP: rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, dexamethasone.
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(GVHD) in one of the patients, no serious transplanta-
tion-related complications have occurred.
Case 1
An 87-year-old woman presented with necrotizing gingi-
vitis of unknown origin. She reported an approximately 
2-month history of painful oral aphtous stomatitis and 
gingival bleeding. Initial treatment with disinfecting 
rinsing agents (for aphtous stomatitis) remained inef-
fective. Clinical examination (Fig. 1a) revealed a solitary 
greyish, infiltrated and ulcerated plaque on the upper 
palate and multiple enoral small aphtous ulcerations. An 
enoral biopsy was performed (Fig. 1b), which showed 
a CD3+/CD2+, cytotoxic (perforin+/granzyme B+/TIA1–/
TdT–), highly proliferative infiltrate. The cells exhibited 
partial (30%) co-expression of CD30 and CD56, but 
were completely negative for CD4, CD8, CD5 and CD7. 
TCRγ/δ gamma (but not TCR-β-F1) and EBV-encoded 
small nuclear RNA (EBER) was found on/in the tumoural 
cells, thus allowing us to diagnose an EBV-associated 
ENKTL nasal type with γ/δ TCR expression. Positron 
emission tomography–computed tomography (PET-CT) 
showed multiple metabolically active focuses and bone 
lesions (spine). 
Because of the aberrant CD30 expression, we aimed 
for systemic treatment with brentuximab-vedotin, an 
antibody-drug conjugate of an anti-CD30 monoclonal 
antibody and the proapoptotic anti-tubulin agent mo-
nomethyl auristatin E (28–30). However, the patient 
declined any lymphoma-specific intervention, and died 
from disease progression (Fig. 1c) and sepsis 64 day 
after diagnosis.
Case 2
A 51-year-old woman presented with a corticosteroid-
resistant nodule on her right lower leg. The patient was 
otherwise asymptomatic and related the nodule to a 
mosquito bite received a few weeks earlier. Clinical 
examination (Fig. 2a) showed a solitary erythematous 
subcutaneous nodule on the right calf, which was firm 
Fig. 1. Case 1. (A) Initial clinical presentation. (B) Immunohistopathological features (HE: haematoxylin and eosin) and expression of immunophenotypical 
markers. (C) Clinical presentation after 3 weeks.
Fig. 2. Case 2. (A) Initial clinical presentation. (B) Immunohistopathological features (HE: haematoxylin and eosin) and expression of immunophenotypical 
markers. (C) Clinical presentation after 2.5 years (left), lichenoid features of cutaneous graft-versus-host disease. 
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and painful on palpation. There was no additional cuta-
neous involvement and no lymphadenopathy. 
Skin biopsy (Fig. 2b) revealed a small-to-medium-
sized pleomorphic, highly proliferative CD3+/CD2+ 
T-cell population with CD8 expression in approxima-
tely 30% of all T cells. Skin flow cytometry (Fig. 2d) 
demonstrated a clearly defined CD16+/CD56+ NK-cell 
population. Molecular analysis did not detect any clonal 
rearrangement of the TCR, immunohistochemistry was 
negative for TCR γ/δ or β-F1 (TCR α/β) and EBV in situ 
hybridization was highly positive. PET-CT excluded na-
sal involvement and systemic dissemination, confirming 
our diagnosis of an extranasal EBV+ ENKTL. 
Following initially successful radiation therapy (6×20 
Gy), a local relapse occurred (Fig. 2a). Our subsequent 
therapeutic approaches with combined methotrexate/
interferon/percutaneous radiotherapy and methotrexate/
asparaginase/dexamethasone remained ineffective. 
Following 2 cycles of SMILE chemotherapy (dexame-
thasone, methotrexate, ifosfamide, Peg-asparaginase, 
and etoposide) and an allogeneic HSCT with reduced 
intensity conditioning, the patient achieved a partial 
remission, accompanied by an acute and, subsequently, 
chronic cutaneous GVHD (superficial sclerosis, lichenoid 
oral involvement). The patient remained relapse-free 
for 18 months (Fig. 2c) before a massive pericardial 
effusion with tumour cells occurred and she died from 
progressive disease. 
Case 3 
A 69-year-old woman presented with newly developed 
generalized ulcerations and pruritus. The patient reported 
a 3-month history of weight loss and night sweats. Mul-
tiple sharply demarcated targetoid erythematous patches 
and plaques were found on the trunk and extremities, 
most of them centrally ulcerated, and painful upon palpa-
tion (Fig. 3a). Mucosal sites were not involved. 
Skin biopsy (Fig. 3b) revealed a prominent lymphocy-
tic infiltrate exhibiting an aberrant cytotoxic phenotype. 
The tumour cells were negative for CD3, CD4, CD30, 
CD7 and CD56, and EBV (EBER1) with low CD8, but 
high expression of the cytotoxic molecules perforin 
and granzyme B. TCR genotyping revealed 2 clonal 
fragments (201/202bp and 204/205bp). Chromosomal 
translocation analysis was unremarkable. A PC-AETCL 
was diagnosed with an aberrant immune phenotype 
and partial loss of CD8 expression. Examination of 
the peripheral blood and the bone marrow showed no 
abnormalities, and a total body CT further excluded ex-
tracutaneous organ involvement (Fig. 3d). Skin-directed 
treatment with class IV topical corticosteroids, polido-
canol and disinfectant bathes remained ineffective. Ad-
ministration of bexarotene (300 mg/d) and methotrexate 
(20 mg/week) combined with local radiotherapy resulted 
in partial healing of the lesions. Two months later, the 
patient developed generalized painful, centrally necrotic 
plaques (Fig. 3c) with high metabolic activity in PET-CT. 
Following 1 cycle of chemotherapy with pegylated lipo-
somal doxorubicin (20 mg/m2), her condition deteriorated 
and she developed new ulcerating lesions, extensive oral 
candidiasis, fever, leukocytopaenia and hyperchromic 
macrocytic anaemia. The patient died from a skin infec-
tion with S. aureus and subsequent sepsis 93 days after 
the initial diagnosis of PC-AETCL. 
Fig. 3. Case 3. (A) Initial clinical presentation. (B) Immunohistopathological features (HE: haematoxylin and eosin) and expression of immunophenotypical 
markers. (C) Clinical presentation after 3 months. (D) Positron emission tomography–computed tomography (PET-CT) at initial staging and 3.5 months 
after diagnosis.
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Case 4 
A 56-year-old man presented with disseminated ulcera-
ting skin nodules, oral necrotic ulcerations and axillary 
and cervical lymphadenopathy. The oral ulcerations had 
appeared 4 months earlier and had been treated unsuc-
cessfully with disinfecting solution. The lesions on the 
trunk and extremities had developed approximately 
1 month later (Fig. 4a). In addition, the patient had a 
2-week history of decreased appetite, weight loss and 
night sweats. The detailed medical history revealed 
chronic lymphocytic leukaemia followed up with 
watchful waiting during the last 6 years. Clinical 
examination (Fig. 4a) revealed disseminated, painful, 
centrally ulcerating nodular lesions (up to 5 cm in 
size), one large oral necrotic plaque and generalized 
lymphadenopathy. 
A skin biopsy (Fig. 4b) revealed a CD3+/CD8+/CD4–/
TCRβ–F1+ proliferative infiltrate of small atypical lym-
phocytes accumulating in the perivascular and periad-
nexal areas. Molecular analysis demonstrated a clonal 
rearrangement of the TCR. PET-CT (Fig. 4d) revealed 
multiple metabolically active cutaneous and subcutane-
ous lesions and generalized lymphadenopathy. Histology 
confirmed further T-cell lymphoma involvement in the 
lymph nodes and in the bone marrow. The patient was 
diagnosed with a PC-AETCL as a composite lymphoma 
with B-cell chronic lymphocytic leukemia (CLL) and 
initiated treatment with R-CHOEP (rituximab, cyclo-
phosphamide, doxorubicin, vincristine, etoposide and 
dexamethasone). After 6 cycles, the patient achieved 
complete remission, which allowed for a reduced con-
ditioning regimen (fludarabine 30 mg/m2, busulfan 4×1 
mg/kg and ATG 10 mg/kg), and an allogeneic HSCT of 
a human leukocyte antigen (HLA)-identical donor (the 
patient’s brother). The first 9 months of follow-up were 
uneventful (Fig. 4c, d). Afterwards, the CLL relapsed and 
the patient developed a spontaneous bacterial peritonitis 
with a septic shock and died.
DISCUSSION
This monocentric cross-sectional case study aimed to 
summarize our experience with aggressive rare T-cell 
lymphomas with skin manifestation. In 4 consecutive 
years, we observed 4 cases: 2 with ENKTL and 2 with 
PC-AETCL. All cases harboured major diagnostic and 
therapeutic challenges. 
The particular oral manifestation of the ENKTL 
(case number 1) and the PC-AETCL (case number 4) 
led to a significant diagnostic and therapeutic delay. In 
contrast, the cutaneous ENKTL nodule (case number 2) 
and the fulminant skin ulcerations of the PC-AETCL 
(case number 3) were clinically much more suggestive 
of lymphoma and thus immediately biopsied (31). This 
emphasizes the importance of a rapid histological exami-
nation on encountering treatment-refractory oral lesions. 
Treatment modalities for ENKTL include radiotherapy, 
chemotherapy, or a combination of both (32). L-aspara-
ginase has shown good in vitro anti-NK-cell lymphoma 
activity, and the introduction of chemotherapeutic re-
giments including L-asparaginase has improved the 
outcome or ENKTL (32). Allogeneic HSCT is reserved 
for patients with relapsed/refractory disease; in a cohort 
of 18 patients, allogeneic HSCT resulted in a 5-year-
Fig. 4. Case 4. (A) Initial clinical presentation. (B) Immunohistopathological features (HE: haematoxylin and eosin) and expression of immunophenotypical 
markers. (C) Clinical presentation after 4 months. (D) Positron emission tomography–computed tomography (PET-CT) at initial staging and after 6 months 
following haematopoietic stem cell transplantation.
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progression-free survival of 57% (33). Our patient with 
ENKTL (case 2) achieved and maintained remission for 
approximately 18 months.
In terms of therapy with the anti-CD30 brentuximab 
vedotin, the significance of CD30 expression in ENKTL 
is still under debate. While Feng et al. found that CD30 
expression (observed in 47.3% of a cohort of 91 patients) 
did not correlate with clinicopathological or prognostic 
features (34), Wang et al. reported an association with 
shorter overall and progression-free survival (35). The 
use of the anti-CD30 brentuximab vedotin has resulted 
in complete remission in 2 cases reported so far (28, 30). 
PC-AETCLs constitute a rare, poorly characterized 
subgroup of cutaneous lymphoma and are, according 
to the 2016 WHO classification, still considered as a 
provisional entity (9). A recent analysis of data from 34 
patients with PC-AETCL confirms poor prognosis, with 
a 5-year survival rate of 32% and a median survival of 
only 12 months (36). Autologous/allogeneic HSCT has 
shown promising results in several recently published 
cases (36, 37). One of our 2 PC-AETCL patients (case 
number 3) did not respond well to treatment with bexa-
rotene, methotrexate, local radiotherapy and pegylated 
liposomal doxorubicin and died of progressive disease 
and sepsis. Our second patient with PC-AETCL (case 
number 4) achieved a remission of at least 9 months after 
R-CHOEP and allogeneic HSCT. 
In conclusion, our experience with rare ENKTL and 
PC-AETCL emphasizes the importance of an early 
extensive diagnostic work-up and prompt aggressive 
therapeutic approach including allogeneic HSCT.
ACKNOWLEDGEMENTS
This study was supported by the Helmut Horten Stiftung (to E.G.), 
the Promedica Stiftung (1406/M and 1412/M to E.G.), the Krebs-
liga Schweiz (KFS-4243-08-2017 to E.G.), the Forschungskredit 
of the University of Zurich (FK-15-040 to W.H. and FK-17-023 
to Y.T.C.), the Jubiläumsstiftung von SwissLife (to E. G.) and the 
Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2 
Immunologie to W.H.) Schweiz. The funders had no role in the 
study design, data collection and analysis, decision to publish, or 
preparation of the manuscript.
The authors have no conflicts of interest to declare.
REFERENCES
1. Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E, 
Wechsler J, Bagot M. Relative frequency and survival of 
patients with primary cutaneous lymphomas: data from a 
single-centre study of 203 patients. Br J Dermatol 2006; 
154: 1206–1207.
2. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous 
lymphoma incidence patterns in the United States: a 
population-based study of 3884 cases. Blood 2009; 113: 
5064–5073.
3. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas 
reported to the National Cancer Institute’s surveillance, epi-
demiology, and end results program: applying the new WHO-
European Organisation for Research and Treatment of Cancer 
classification system. J Clin Oncol 2005; 23: 7246–7248.
4. Eder J, Kern A, Moser J, Kitzwogerer M, Sedivy R, Trautinger 
F. Frequency of primary cutaneous lymphoma variants in 
Austria: retrospective data from a dermatology referral cen-
tre between 2006 and 2013. J Eur Acad Dermatol Venereol 
2015; 29: 1517–1523.
5. Jenni D, Karpova MB, Seifert B, Golling P, Cozzio A, Kempf W, 
et al. Primary cutaneous lymphoma: two-decade comparison 
in a population of 263 cases from a Swiss tertiary referral 
centre. Br J Dermatol 2011; 164: 1071–1077.
6. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary 
syndrome and mycosis fungoides arise from distinct T-cell 
subsets: a biologic rationale for their distinct clinical beha-
viors. Blood 2010; 116: 767–771.
7. DeSimone JA, Sodha P, Ignatova D, Dummer R, Cozzio A, 
Guenova E. Recent advances in primary cutaneous T-cell 
lymphoma. Curr Opin Oncol 2015; 27: 128–133.
8. Mangold AR, Thompson AK, Davis MD, Saulite I, Cozzio A, 
Guenova E, et al. Early clinical manifestations of Sezary 
syndrome: a multicenter retrospective cohort study. J Am 
Acad Dermatol 2017; 77: 719–727.
9. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert 
R, et al. The 2016 revision of the World Health Organiza-
tion classification of lymphoid neoplasms. Blood 2016; 127: 
2375–2390.
10. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein 
H, et al. World Health Organization classification of tumors 
of haematopoietic and lymphoid tissues. 4th edn. Lyon: 
IARC; 2008.
11. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, 
et al. WHO-EORTC classification for cutaneous lymphomas. 
Blood 2005; 105: 3768–3785.
12. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein 
H, et al. World Health Organization classification of tumours 
of haematopoietic and lymphoid tissues, revised 4th edition. 
Lyon: IARC; 2017.
13. Linke-Serinsoz E, Fend F, Quintanilla-Martinez L. Human 
immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) 
related lymphomas, pathology view point. Semin Diagn 
Pathol 2017; 34: 352–363.
14. Vose J, Armitage J, Weisenburger D, International TCLP. 
International peripheral T-cell and natural killer/T-cell lymp-
homa study: pathology findings and clinical outcomes. J Clin 
Oncol 2008; 26: 4124–4130.
15. Suzuki R. Pathogenesis and treatment of extranodal natural 
killer/T-cell lymphoma. Semin Hematol 2014; 51: 42–51.
16. Jhuang JY, Chang ST, Weng SF, Pan ST, Chu PY, Hsieh PP, et 
al. Extranodal natural killer/T-cell lymphoma, nasal type in 
Taiwan: a relatively higher frequency of T-cell lineage and 
poor survival for extranasal tumors. Hum Pathol 2015; 46: 
313–321.
17. Shet T, Suryawanshi P, Epari S, Sengar M, Rangarajan V, Me-
non H, et al. Extranodal natural killer/T cell lymphomas with 
extranasal disease in non-endemic regions are disseminated 
or have nasal primary: a study of 84 cases from India. Leuk 
Lymphoma 2014; 55: 2748–2753.
18. Guenova E, Ghoreschi K, Hotzenecker W, Mailhammer R, 
Weindl G, Sauer K, et al. Systemic IL-4 therapy abrogates 
IL-23 secretion and Th17 responses in psoriasis. Exp Der-
matol 2009; 18: 293.
19. Kato S, Asano N, Miyata-Takata T, Takata K, Elsayed AA, 
Satou A, et al. T-cell receptor (TCR) phenotype of nodal 
Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma 
(CTL): a clinicopathologic study of 39 cases. Am J Surg Pathol 
2015; 39: 462–471.
20. Hong M, Lee T, Young Kang S, Kim SJ, Kim W, Ko YH. Nasal-
type NK/T-cell lymphomas are more frequently T rather than 
NK lineage based on T-cell receptor gene, RNA, and protein 
studies: lineage does not predict clinical behavior. Modern 
Pathol 2016; 29: 430–443.
21. Pongpruttipan T, Sukpanichnant S, Assanasen T, Wanna-
krairot P, Boonsakan P, Kanoksil W, et al. Extranodal NK/T-cell 
lymphoma, nasal type, includes cases of natural killer cell and 
alphabeta, gammadelta, and alphabeta/gammadelta T-cell 
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
7Rare T-cell lymphomas
Acta Derm Venereol 2018
origin: a comprehensive clinicopathologic and phenotypic 
study. Am J Surg Pathol 2012; 36: 481–499.
22. Takata K, Hong ME, Sitthinamsuwan P, Loong F, Tan SY, Liau 
JY, et al. Primary cutaneous NK/T-cell lymphoma, nasal type 
and CD56-positive peripheral T-cell lymphoma: a cellular 
lineage and clinicopathologic study of 60 patients from Asia. 
Am J Surg Pathol 2015; 39: 1–12.
23. Kikuchi Y, Kashii Y, Gunji Y, Morimoto A, Masuzawa A, 
Takatsuka Y, et al. Six-year-old girl with primary cutaneous 
aggressive epidermotropic CD8+ T-cell lymphoma. Pediatr 
Int 2011; 53: 393–396.
24. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Wil-
lemze R. Primary cutaneous CD8-positive epidermotropic 
cytotoxic T cell lymphomas. A distinct clinicopathological 
entity with an aggressive clinical behavior. Am J Pathol 1999; 
155: 483–492.
25. Mangana J, Guenova E, Kerl K, Urosevic-Maiwald M, Amann 
VC, Bayard C, et al. Angioimmunoblastic T-cell lymphoma 
mimicking drug reaction with eosinophilia and systemic 
symptoms (DRESS syndrome). Case Rep Dermatol 2017; 
9: 74–79.
26. Magana M, Massone C, Magana P, Cerroni L. Clinicopathologic 
features of hydroa vacciniforme-like lymphoma: a series of 
9 patients. Am J Dermatopathol 2016; 38: 20–25.
27. Fardet L, Galicier L, Vignon-Pennamen MD, Regnier S, No-
guera ME, de Labarthe A, et al. Frequency, clinical features 
and prognosis of cutaneous manifestations in adult patients 
with reactive haemophagocytic syndrome. Br J Dermatol 
2010; 162: 547–553.
28. Poon LM, Kwong YL. Complete remission of refractory disse-
minated NK/T cell lymphoma with brentuximab vedotin and 
bendamustine. Ann Hematol 2016; 95: 847–849.
29. Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS. 
Complete remission in CD30-positive refractory extranodal 
NK/T-cell lymphoma with brentuximab vedotin. Blood Res 
2015; 50: 254–256.
30. Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim CW, et al. 
Prognostic implications of CD30 expression in extranodal 
natural killer/T-cell lymphoma according to treatment mo-
dalities. Leuk Lymphoma 2015; 56: 1778–1786.
31. Jo JC, Yoon DH, Kim S, Lee BJ, Jang YJ, Park CS, et al. Clini-
cal features and prognostic model for extranasal NK/T-cell 
lymphoma. Eur J Haematol 2012; 89: 103–110.
32. Tse E, Kwong YL. The diagnosis and management of NK/T-cell 
lymphomas. J Hematol Oncol 2017; 10: 85.
33. Tse E, Chan TS, Koh LP, Chng WJ, Kim WS, Tang T, et al. 
Allogeneic haematopoietic SCT for natural killer/T-cell lymp-
homa: a multicentre analysis from the Asia Lymphoma Study 
Group. Bone Marrow Transplant 2014; 49: 902–906.
34. Feng Y, Rao H, Lei Y, Huang Y, Wang F, Zhang Y, et al. CD30 
expression in extranodal natural killer/T-cell lymphoma, 
nasal type among 622 cases of mature T-cell and natural 
killer-cell lymphoma at a single institution in South China. 
Chin J Cancer 2017; 36: 43.
35. Wang GN, Zhao WG, Li L, Zhang DD, Gao XZ, Zhou J, et al. 
Prognostic significance of CD30 expression in nasal natural 
killer/T-cell lymphoma. Oncol Lett 2017; 13: 1211–1215.
36. Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, 
Olsen EA, et al. Primary cutaneous aggressive epidermotropic 
cytotoxic T-cell lymphomas: reappraisal of a provisional en-
tity in the 2016 WHO classification of cutaneous lymphomas. 
Modern Pathol 2017; 30: 761–772.
37. Plachouri KM, Weishaupt C, Metze D, Evers G, Berdel WE, 
Kempf W, et al. Complete durable remission of a fulminant 
primary cutaneous aggressive epidermotropic CD8+ cy-
totoxic T-cell lymphoma after autologous and allogeneic 
hematopoietic stem cell transplantation. JAAD Case Rep 
2017; 3: 196–199.
